The biotech company presented solid data for a candidate that could eventually rival blockbuster weight loss drugs from big ...
Eli Lilly (NYSE: LLY) and Novo Nordisk(NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback